Skip to main content
Premium Trial:

Request an Annual Quote

Proteintech Acquires Recombinant Reagent Manufacturer ChromoTek

NEW YORK ─ Proteintech on Tuesday announced the acquisition of Munich-based ChromoTek, a manufacturer of single-domain antibodies, for an undisclosed amount.

The combined companies will better address growing opportunities and challenges in single-cell analysis, super-resolution imaging, and multiplex assays, and better serve research, translational science, and therapeutic applications, according to Chicago-based Proteintech, a manufacturer of antibodies, proteins, and immunoassays.

ChromoTek's Camelid single-domain antibodies, also known as nanobodies, are recombinant reagents used for research.

Marion Jung, CEO of ChromoTek, said in a statement that the firm's fit-for-purpose nanobody-based tools complement the antibody coverage offered by Proteintech.